Aim: To investigate the effects of GABA and glycine on analgesia in the central nervous system. Methods: Glycine, taurine, or muscimol was injected with bicuculline into the cistern magna or the lumbar subarachnoidal space in ICR mice. The effects on bicuculline-induced allodynia in a touch-evoked agitation test and on pain threshold index in a hot-plate test were assessed. Results: The dosages of the amino acids administered with bicuculline had no effect on motor behavior in conscious mice. Glycine or muscimol reduced bicuculline-induced allodynia regardless of the administration site, whereas intrathecal taurine reduced bicucullineinduced allodynia. Glycine, taurine, and muscimol all antagonized the effects induced by bicuculline in the hot-plate test, regardless of the administration site. Conclusion: Glycine, taurine, and muscimol were found to have anti-allodynic and anti-thermal hyperalgesic properties in vivo. These observations suggest an interaction between glycine and GABA receptors during the regulation of antinociception.
Introduction γ-Aminobutyric acid (GABA) and glycine are important inhibitory neurotransmitters in the mammalian central nervous system (CNS) [1] . The activation of glycine receptors typically yields an anti-nociceptive response [2] . However, the acute antagonism of spinal GABA A receptors exhibited by bicuculline produces touch-evoked agitation (allodynia) [3] . GABA and glycine are colocalized in interneurons in spinal laminae I-III [4, 5] and are coreleased from the same interneurons [6] . However, taurine binds to glycine receptors in the CNS and functions as a partial agonist of GABA A receptors [7] , inhibiting behaviors evoked by intrathecal N-methyl-D-aspartate (NMDA) or kainate injection [8, 9] . If GABA and glycine are coreleased from the same interneurons, and glycine-related amino acids act at GABA and glycine receptors to modulate low-threshold transmission via distinct but complementary mechanisms, then glycine or its related amino acids might inhibit bicuculline-induced allodynia.
However, the nature of the interaction between glycine and GABA during sensory modulation is unclear.
We undertook this study with the following objectives. First, we wanted to determine whether central glycine, taurine, or muscimol (GABA A receptor agonist) can produce analgesia. Second, we wanted to know whether glycine, taurine, or muscimol can antagonize bicuculline-induced allodynia and heat hyperalgesia.
Materials and methods

Animals
This study was conducted after obtaining approval from the Animal Care Committee of Korea University. Male ICR mice weighing 23-27 g were housed one per cage before experiments in an environmentally controlled room (22±2 ºC, relative humidity 55%±5%) under a 12 h:12 h light cycle (lights on at 7:00 am) with free access to food and water.
Drugs
Solutions were prepared in artificial cerebrospinal fluid (aCSF) containing (in mmol/L): 124 NaCl, 26 NaHCO 3 , 1.25 NaH 2 PO 4 , 2.5 KCl, 2 MgCl 2 , 2 CaCl 2 , and 10 dextrose. The solution pH
Intracisternal or intrathecal glycine, taurine, or muscimol inhibit bicuculline-induced allodynia and thermal hyperalgesia in mice Intracisternal injections Anesthesia was induced using 4% sevoflurane in air in a 500-mL induction chamber. A rubber facemask was used to maintain anesthesia (sevoflurane 4% through a Mapleson D circuit) and to immobilize the mouse's head. In addition, mice were placed in a holder molded from modeling clay to fit the body. A space was molded in the posterior neck area to allow the region between the occiput and atlas to be palpated as well as to facilitate injection. Intracisternal injections were performed using a 25-µL Hamilton syringe (Hamilton Co, NV, USA) attached to a 27-G stainless steel needle, the tip of which was modified with a stopper to ensure an insertion depth of 2.4 mm. The needle was carefully advanced to the cistern magna; after the injection had been made, the syringe was held in position for a few seconds and then gradually removed to avoid drug outflow along the needle tract. Injection sites were verified by injecting a similar volume of 1% methylene blue solution and then confirming the distribution of dye in the cisternal space. Throughout the experiment, the dye was found to distribute throughout the cistern magna space and to reach the occipital surface of the brain and the upper cervical portion of the spinal cord. The experimenter was trained using dye injections prior to beginning the experiments and achieved an accuracy of >98% in other mice. The entire injection procedure, including anesthesia, took about three min. Spontaneous face scratching or touch-evoked allodynia of the face was observed after the injection of bicuculline.
Intrathecal injection
All intrathecal injections were made at the L5-L6 intervertebral space using a 30-gauge 0.5-inch needle mounted on a 25-µL Hamilton syringe, as previously described by Hylden and Wilcox [10] . Injection sites were verified by injecting a similar volume of 1% methylene blue solution and determining the distribution of the dye in the spinal cord. In this case, the dye was distributed rostrally and caudally but over a short distance (less than 1 cm). No dye was found in the brain. The experimenter was similarly trained using dye prior to experiments, and achieved an accuracy of >95%. The entire injection procedure, including handling, also took about three minutes. Spontaneous tail-biting as well as touch-evoked allodynia of hind feet and tail was observed after mice were injected with bicuculline.
Experimental protocol
To examine the effects of different doses of bicuculline, 5 µL of bicuculline at concentrations of 2.5 µmol (0.0045925 µg), 5 µmol (0.009185 µg), 7.5 µmol (0.0137775 µg), or 20 µmol (0.03674 µg) was injected intracisternally or intrathecally. Two of the four mice treated with 0.0045925 µg of bicuculline administered intracisternally failed to show allodynia to light touch. However, 0.009185 µg administered intracisternally induced consistent touch-evoked allodynia, and two mice of the four mice treated with 0.03674 µg exhibited convulsive behavior (body rollover, loss of postural control, falling, motor arrest with myoclonic jerks, and frequent dyskinesia) [11, 12] . Accordingly, we chose to use 0.009 µg of bicuculline to induce allodynia in all subsequent experiments.
To determine the appropriate dose of muscimol, we injected 5 µL at concentrations of 0.025 mmol (0.0142625 µg), 0.05 mmol (0.028525 µg), 0.25 mmol (0.142625 µg), 0.5 mmol (0.28525 µg), or 5 mmol (2.8525 µg). Mice administered 0.28525 µg intracisternally were sedated for more than 4 min or showed intermittent dyskinetic hyperactivity; we were unable to perform the hot-plate test on these mice. Mice administered 2.8525 µg of muscimol intrathecally showed paresis of both hind limbs for more than 2 h. Finally, we chose muscimol doses of 0.01, 0.02, and 0.1 µg for subsequent experiments.
Similarly, preliminary experimentation indicated that analgesic doses of 25 µg for glycine and of 40 µg for taurine (the molar equivalent of the glycine 25 µg dose (66 mmol)) were optimal for both intracisternal and intrathecal injections. The dosages of glycine, taurine, muscimol, and bicuculline used had no effect on motor behavior in conscious mice.
Study design
Experiments were performed in a blinded and randomized fashion. The experimenter who injected the drug and the observer were unaware of which drug had been administered. Drug and control solutions were injected in a random, computer-generated order (http://www.randomizer.org). Animals were subjected to one treatment only. Allodynia and hot-plate test sessions were conducted for 60 min after drug injections. Experiments were conducted between 9:00 am and 4:00 pm in a quiet room.
The mice were divided into two main experimental groups: the allodynia test group and the hot-plate test group. Control mice were given 5 μL of bicuculline (n=8) or aCSF as vehicle (n=8) only. The two experimental groups were divided randomly in subgroups: vehicle control (n=8), glycine (5, 10, or 25 µg) (n=8, per dosage), taurine (10, 20, or 40 µg) (n=8, per dosage), and muscimol (0.01, 0.02, 0.1 µg) (n=8, per dosage). Each mouse in the experimental groups received bicuculline in combination with one of the study drugs above. When the combined effects of drugs were examined, the drugs were coadministered intracisternally or intrathecally to ensure their co-localization and to minimize injection volumes. After injections, mice in the allodynia test group were placed individually in transparent plastic cages (30 cm long, 15 cm high, and 15 cm wide) for observation, whereas mice in the hot-plate test group were placed on a clear glass plate. Timing started after injections were complete. 
Allodynia test
We tested for allodynia using a paintbrush by touching face fur (after intracisternal injection) or hind foot or tail bare skin (after intrathecal injection) in a rostro-caudal sequence (face, hind foot, tail).
These stimuli in treatment naive or vehicle (aCSF)-control mice were insufficient to cause scratching or attempts to escape. Behavioral responses were quantified by a second experimenter. Touch-evoked agitation was checked every 5 min until 60 min after drug injection. Normal quiescent behavior, that is, grooming, sniffing, and exploring the environment, was not included. Touch-evoked agitation was ranked as described by Minami et al [13] : 0=no response; 1=mild squeaking with attempts to move away from the probe; and 2=vigorous squeaking, biting of the probe, vigorous scratching, tail flicking, or biting of the tail and vigorous attempts to avoid the probe. Values are the averages of total scores at each time point (maximal possible score at each time point=2/mouse). Allodynia scores were calculated by summing the numbers of positive responses every 5 min for 60 min. This overall test time was chosen based on the findings of preliminary studies; these studies showed that touchevoked behavioral responses continued for 45 min after the injection of bicuculline and gradually diminished thereafter. All experiments were recorded using a video camera (Sony) and then saved to computer file.
Hot-plate test
Mice were allowed to acclimate within an acrylic enclosure on a clear glass plate before the experiment. A radiant heat source was then focused onto the plantar surface of a hind paw. The test involved placing a mouse on a hot plate maintained at 55 ºC and recording the time to first response (foot licking, jumping, or rapidly removing paws), as described by Minami et al [14] . A timer stopped automatically when withdrawal of the paw was detected by a photodetector (a cut-off value of 30 s was used to prevent tissue damage). Response times were measured twice at 5-min intervals and mean values were considered as pain thresholds. Basal pain thresholds were measured before drug administration (time=0). Responses were observed at 15, 30, 45, and 60 min after drug injection. These times were chosen based on the results of preliminary studies, which showed that hot plate response peaked between 30 and 45 min after the injection of bicuculline.
For analysis purposes, all response latencies were expressed as hot-plate test pain indices (HPPI) where:
Sedation assay A mouse was placed on a rubber cylinder (height 2.5 cm, diameter 6 cm) after drug or vehicle administration [15] . We recorded the time that elapsed before the mouse jumped off the rubber cylinder. When time taken to step off the rubber was longer than that observed among controls, sedation had been achieved.
Statistical analysis
Sedation results were analyzed using the binomial test. Allodynia scores or hot-plate test results were analyzed by ANOVA (analysis of variance). Post-hoc analysis was performed using Dunn's test or Holm-Sidak methods. Student's two-tailed test was used to compare two means. The level of significance was set at 5% (P<0.05). Data are presented as means±SEM. Statistical analysis was performed using SigmaStat 3.0 (Systat Software Inc, Chicago).
Results
Effects of glycine, taurine, or muscimol on bicuculline-induced allodynia Treatment with glycine, taurine, or muscimol failed to induce significant allodynia at the doses used, and no significant difference was observed between the allodynia scores of experimental groups and the vehicle controls. Animals treated intracisternally or intrathecally with bicuculline had higher cumulative allodynia scores than animals treated with aCSF (n=8, P<0.05 vs aCSF vehicle controls, Figure 1 ).
In the glycine, taurine, or muscimol+bicuculline groups, glycine (25 µg) and muscimol (0.1 µg) significantly reduced bicuculline-induced allodynia, regardless of administration site (n=8, P<0.05 vs bicuculline+aCSF). Furthermore, intrathecal taurine (40 µg) significantly reduced bicuculline-induced allodynia (n=8, P<0.05 vs bicuculline+aCSF) ( Table 1) .
Effects of glycine, taurine, or muscimol on bicuculline-induced thermal hyperalgesia The basal latencies of conscious mice as measured by the hotplate test were similar before drug injection. Mice administered intracisternal glycine (25 µg) alone had a higher HPPI at 15 min than at baseline (time=0); this value was also higher than that of vehicle controls (P<0.05). When given alone, intrathecal glycine, taurine, or muscimol had no effect on the pain threshold index (P>0.05 vs vehicle controls) (data not
HPPI=
Pain threshold by the hot-plate test Basal pain threshold by the hot-plate test In the glycine, taurine, or muscimol+bicuculline groups, glycine (intracisternal 25 µg or intrathecal 10, 25 µg) increased the HPPI (P<0.05 vs bicuculline+aCSF) ( Figure 3A, 3B) . Taurine (intracisternal 40 µg or intrathecal 20, 40 µg) increased the HPPI (P<0.05 vs bicuculline+aCSF group) ( Figure 4A, 4B) . Similarly, muscimol (intracisternal 0.l µg, or intrathecal 0.02, 0.1 µg) also increased the HPPI (P<0.05 vs bicuculline+aCSF group) ( Figure 5A , 5B).
In the glycine, taurine, or muscimol+bicuculline groups, intracisternal glycine, taurine, or muscimol increased the HPPI at 60 min (P<0.05 vs baseline) ( Figure 3A, 4A, 5A ). In the glycine, taurine, or muscimol+bicuculline groups, intracisternal muscimol increased the HPPI at 45 min (P<0.05 vs baseline), and intrathecal muscimol or taurine increased the pain threshold from 15 to 60 min (P<0.05 vs baseline) ( Figure 4B , 5B). The intrathecal administration of muscimol and taurine had more prolonged anti-hyperalgesic effects than did intracisternal administration, as determined by the hot-plate test (Figure 4 , 5).
Side effects of glycine, taurine, and muscimol Sedation was not observed in mice injected intracisternally or intrathecally with glycine, taurine, or muscimol ( Table 2) .
Discussion
The present study demonstrates that centrally administered glycine, taurine, or muscimol can produce analgesia and that GABA A receptor antagonists produce thermal hyperalgesia.
On the other hand, glycine, muscimol, or intrathecal taurine was found to reduce bicuculline-induced allodynia, and to Values are expressed as means±SEMs (n=8 mice per group). Each mouse was placed on a rubber cylinder after drug injection. Latency to step off the rubber cylinder with the hind paw was recorded. Data were analyzed using one-way ANOVA. No significant difference was observed between drug injected mice and vehicle (aCSF) controls.
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The anti-allodynic effects of glycine, taurine, and muscimol In the present study, glycine was found to reduce bicucullineinduced allodynia. This result is consistent with the finding that glycine and GABA are coreleased from the same interneurons [6] . Because spinal glycine and GABA A receptors are localized on the same postsynaptic membranes [4, 5] , this finding suggests that GABA and glycine work together to affect sensory modulation. Furthermore, Todd and colleagues reported that both GABAergic and glycinergic neurons are present in spinal Rexed laminae II-IV and that fibers form axoaxonic synapses on Aβ terminals and on the wide dynamic range neurons [5] . The authors also reported that glycine immunoreactivity in laminae I-III is restricted to neurons that also contain GABA and that 50% of the GABA-immunoreactive neurons also contain glycine [3, 16] . In the present study, we found that blockade of GABA A receptors by centrally administered bicuculline evoked allodynia and that this effect is attenuated by glycine administration.
Our study also shows that intrathecal taurine reduced bicuculline-induced allodynia in our ICR mouse model. Although not directly comparable, the results of the present study are consistent with the results obtained by Jiang et al, namely, that taurine (300 µmol) binds primarily to the glycine receptor; however, at high concentrations, taurine (10 mmol) can also activate GABA A receptors in vitro [7] . In fact, Idrissi and Trenkner reported that taurine interacts directly with GABA A receptor in vitro [17] . These findings led us to speculate that GABA A receptor blockade might be modulated by taurine. However, Xu et al concluded that taurine activates glycine receptors rather than GABA A receptors [18] . Although no precise role has been defined for taurine during spinal nociceptive processing, it has been demonstrated that taurine inhibits the behaviors induced by intrathecal NMDA or kainate [8] . In the present study, we found that blockade of GABA A receptors by intrathecal bicuculline evoked allodynia and that this effect is attenuated by intrathecal taurine.
We also found that muscimol reduced bicuculline-induced allodynia, but it did not completely inhibit the effect of bicuculline in our model. We believe that this was due to the dose used, which was chosen specifically to have no effect on motor behavior in conscious mice. Muscimol can impair motor performance in the analgesic dose range (rat, intrathecal injection 0.5-1.0 µg), which is higher than that used in the present study. This result suggests that motor impairment may have impaired the vigorous scratching response or tail flick response to touch stimuli, thereby mimicking analgesia. Several lines of evidence have demonstrated that the stimulation of GABA A receptors by systemic or intracerebroventricular muscimol produces antinociception [19, 20] . Although no direct comparison is possible, central GABA receptors have been demonstrated to participate in the production of antinociception, induced by the stimulation of descending pain inhibition systems. Our findings related to the effect of muscimol on allodynia are consistent with the results above. Furthermore, they indicate that bicuculline evokes allodynia and that muscimol attenuates this effect of bicuculline. Thus, the results of the present study indicate that GABA A receptors are involved in the modulation of pain behavior mediated by GABA A receptor antagonists.
The anti-hyperalgesic effects of glycine, taurine, and muscimol Bicuculline was found to produce thermal hyperalgesia in the present study, which confirms the hypothesis that loss of GABA tone leads to hyperalgesia. The production of thermal hyperalgesia by bicuculline supports the hypothesis proposed by Yamamoto and Yaksh [21] that the loss of spinal bicucullinesensitive inhibition augments development of the thermal hyperalgesia induced by chronic nerve compression. The neural circuitries of thermal hyperalgesia and allodynia appear to differ. In particular, the afferent signals encoding allodynia appear to be encoded by large, myelinated afferent fibers, whereas the signals encoding thermal hyperalgesia are carried by small non-myelinated fibers [22] . Furthermore, thermal hyperalgesia seems to be mediated by pathways intrinsic to the spinal cord, whereas allodynia requires the contribution of supraspinal sites [23] . In the present study, intracisternal or intrathecal glycine, taurine, or muscimol significantly increased the bicucullineinduced pain threshold index, which is consistent with the finding of Simpson et al that intrathecal glycine reduced sensitivity to noxious stimulation [24] . We found that intracisternal taurine transiently inhibited bicuculline-induced thermal hyperalgesia, whereas intrathecal taurine inhibited this pathway for 60 min. We believe that intracisternal administration allows better access to the brainstem and reduces the specificity of spinal cord activity. However, Simpson et al found that glycine reduced thermal hyperalgesia in rats after sciatic nerve ligation for more than 200 min, whereas we observed this effect for only 60 min after intrathecal taurine administration. These differences are probably due to the different experimental models and species used. Furthermore, in the present study, intrathecal glycine failed to elicit any reduction in thermal hyperalgesia over the course of 60 min, whereas intrathecal taurine reduced thermal hyperalgesia significantly over the course of 60 min. According to another study, intrathecal bicuculline alone evokes a transient spinal release of taurine [25] , which suggests that intrathecal taurine could have a longer duration of action than glycine.
Some studies have shown that muscimol has an antinociceptive effect [26] , whereas muscimol is ineffective in the hotplate test [13, 27] . These discrepancies regarding the effects of muscimol in mice may be due to species and drug-loading differences. Aanonsen et al administered muscimol at 0.05 pmol and bicuculline at 1 pmol intrathecally to reverse the inhibition of NMDA-induced tail-flick hyperalgesia induced by muscimol [26] . Hammond et al administered muscimol (0.25 µg) intrathecally in the rat, but found that it did not have an anti-thermal hyperalgesic effect [27] . Minami et al administered muscimol 0.1 µg intrathecally to reverse 0.01-0.1 µg prostaglandin E 2 -induced heat hyperalgesia, but this approach was ineffective [13] . In the present study, we administered 0.01-0.1 µg muscimol (0.25-25 µmol) and 0.009 µg (5 µmol) bicuculline. Analysis of the anti-hyperalgesia produced by muscimol is complicated by the motor effects of the drug. Muscimol impairs motor performance in the analgesic dose range, which suggests that motor impairment may have inhibited withdrawal from the hot plate and thus mimicked anti-hyperalgesia. Furthermore, our finding that muscimol did not produce significant motor dysfunction contrasts with those of previous studies, which found that muscimol produces motor weakness at analgesic doses [27] . Nevertheless, the present study shows that intracisternal or intrathecal GABA A receptor agonists produce intrinsic antinociception. To summarize, glycine, taurine, and muscimol all reduced bicuculline-induced allodynia and thermal hyperalgesia responses in mice. Furthermore, their effects on thermal hyperalgesia were prolonged when administered intrathecally. Thus, glycine-related α-or β-amino acids and GABA A receptor agonists may prevent the binding of GABA A receptor antagonists in the central nervous system, which presents a possible strategy for the treatment of allodynia or hyperalgesia.
